Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PureTech Health (PRTC)
NASDAQ:PRTC
PRTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.00 - $34.00
Previous CloseN/A
Volume2.03K
Average Volume (3M)4.89K
Market Cap
$418.47M
Enterprise Value$448.27M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Apr 24, 2025EPS Estimate
-2.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding23,942,131
10 Day Avg. Volume4,587
30 Day Avg. Volume4,888
Standard Deviation0.14
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)545.64
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-279.65
Enterprise Value/Ebitda-2.65
Forecast
1Y Price Target
$46.00Price Target Upside139.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Business ModelThe hybrid business model of Puretech Health Plc, combining drug development and company incubation, offers multiple ways to succeed over the long term.
Drug DevelopmentLYT-100 is seen as the most promising wholly-owned program within Puretech Health Plc, demonstrating potential as a real drug in the high unmet need and large market opportunity in IPF.
Research And DevelopmentPRTC's 'Hub-and-Spoke' R&D model offers a multitude of growth opportunities in a capital-efficient and risk-sharing manner.
Bears Say
Market AccessibilityThe unique business model and low liquidity for US-listed shares create a barrier to entry for some investors.
Product EfficacyLYT-100 550mg shows more tolerability than pirfenidone, though with modestly lower efficacy, which may limit its appeal.
Stock PerformancePRTC stock continues to be dislocated due to investor base turnover and low liquidity for the ADRs.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors
PRTC FAQ
What was PureTech Health’s price range in the past 12 months?
PureTech Health lowest stock price was $17.00 and its highest was $34.00 in the past 12 months.
What is PureTech Health’s market cap?
PureTech Health’s market cap is $418.47M.
When is PureTech Health’s upcoming earnings report date?
PureTech Health’s upcoming earnings report date is Apr 24, 2025 which is in 76 days.
How were PureTech Health’s earnings last quarter?
PureTech Health released its earnings results on Aug 28, 2024. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$3.03 by $1.53.
Is PureTech Health overvalued?
According to Wall Street analysts PureTech Health’s price is currently Undervalued.
Does PureTech Health pay dividends?
PureTech Health does not currently pay dividends.
What is PureTech Health’s EPS estimate?
PureTech Health’s EPS estimate is -2.83.
How many shares outstanding does PureTech Health have?
PureTech Health has 23,942,131 shares outstanding.
What happened to PureTech Health’s price movement after its last earnings report?
PureTech Health reported an EPS of -$1.5 in its last earnings report, beating expectations of -$3.03. Following the earnings report the stock price went down -6%.
Which hedge fund is a major shareholder of PureTech Health?
Currently, no hedge funds are holding shares in PRTC
---
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (139.83% Upside)
$46.00 (139.83% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.73%
12-Months-Change
Fundamentals
Return on Equity
-19.80%
Trailing 12-Months
Asset Growth
-16.38%
Trailing 12-Months
Company Description
PureTech Health
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastrointestinal and immune systems, and the interactions and signaling between them. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of the society's healthcare needs.
---
PRTC Stock 12 Month Forecast
Average Price Target
$46.00
▲(139.83% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Neurocrine
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering PRTC
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-11.50%
reiterated a buy rating 2 months ago
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -11.50% per trade.
---